F-1/A: Cuprina Holdings Files Amendment No. 4 to Form F-1 for Initial Public Offering

Cuprina Holdings (Cayman) Limited files an amendment to its Form F-1 registration statement for its initial public offering of Class A Ordinary Shares, with a resale prospectus included.

Summary

• Cuprina Holdings (Cayman) Limited has filed Amendment No. 4 to its Form F-1 registration statement with the SEC.
• The filing includes a prospectus for the initial public offering of 3,750,000 Class A Ordinary Shares.
• A resale prospectus is also included, covering the potential resale of 1,500,000 Class A Ordinary Shares by Ms. Dorea Quek En Qi and Mr. Bryan Teo Ying Jie.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR, but approval is pending.
• The offering's closing is contingent upon Nasdaq's final approval of the listing application.
• The company will not receive any proceeds from the sale of Class A Ordinary Shares by the Resale Shareholders.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
• Network 1 Financial Securities, Inc. is the representative and sole book-running manager for the offering.
• The company estimates net proceeds from the offering to be approximately US$[] million, which will be used for growth, R&D, brand awareness, equipment, infrastructure, and loan repayment.
• The company is incorporated in the Cayman Islands and conducts operations primarily in Singapore.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the company's growth strategies and competitive strengths, it also acknowledges significant financial risks and a history of losses. The potential for future growth is balanced by the uncertainty of achieving profitability.

Positives

• The company is expanding its sales and establishing physical operations in key regions, including Southeast Asia, the Middle East, and mainland China.
• The company has attained ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for its manufacturing facility in Singapore.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• An active trading market for the Class A Ordinary Shares may not be established.
• The trading price of the Class A Ordinary Shares may be volatile.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq.
• The company's corporate actions are significantly influenced by its directors, officers and principal shareholders.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.
• The company is subject to various governmental regulations relating to the labeling, marketing and sale of its products.
• The company relies on third parties to manufacture and supply its products, and may encounter delays or incur additional costs when adding/replacing manufacturers and suppliers for its products.

Future Outlook

The company plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China in the second half of 2024 and 2025.

Industry Context

The company operates in the chronic wound care and cosmeceutical industries, which are experiencing growth due to an aging population and increasing prevalence of comorbidities.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• It mentions competitors like Smith & Nephew plc, ConvaTec Group plc, and Mlnlycke Health Care AB, but does not offer a detailed benchmark analysis against these companies.

Related Party Transactions

• The company has engaged in various transactions with related parties, including loans, management fees, and share subscriptions.
• Cuprina Holding Pte. Ltd. has provided advances to the company for working capital purposes.
• Jimmy Lee Peng Siew, a beneficial owner, has provided advances to the company for working capital purposes.

Stakeholder Impact

• Shareholders will be affected by the potential volatility of the Class A Ordinary Shares.
• Shareholders will be affected by the company's ability to execute its growth strategies and achieve profitability.
• Shareholders will be affected by the company's ability to comply with regulatory requirements.
• Employees will be affected by the company's ability to attract, cultivate and retain a talented and professional workforce.

Next Steps

• The company needs to obtain Nasdaq's final approval for its listing application.
• The company plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China in the second half of 2024 and 2025.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.

Key Dates

Keywords

initial public offering, Class A Ordinary Shares, resale prospectus, Cuprina Holdings, Nasdaq, medical devices, wound care, biotechnology, emerging growth company, financial metrics